These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 30253203

  • 21. Brain Exposure to the Macrocyclic ALK Inhibitor Zotizalkib is Restricted by ABCB1, and Its Plasma Disposition is Affected by Mouse Carboxylesterase 1c.
    Rijmers J, Sparidans RW, Acda M, Loos NHC, Epeslidou E, Bui V, Lebre MC, Tibben M, Beijnen JH, Schinkel AH.
    Mol Pharm; 2024 Oct 07; 21(10):5159-5170. PubMed ID: 39312722
    [Abstract] [Full Text] [Related]

  • 22. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554).
    Li W, Sparidans R, El-Lari M, Wang Y, Lebre MC, Beijnen JH, Schinkel AH.
    Int J Pharm; 2020 Jan 05; 573():118842. PubMed ID: 31759109
    [Abstract] [Full Text] [Related]

  • 23. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.
    van Hoppe S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2017 Jun 05; 120():43-50. PubMed ID: 28288939
    [Abstract] [Full Text] [Related]

  • 24. P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib.
    F Martins ML, Loos NHC, Mucuk S, de Jong D, Lebre MC, Rosing H, Tibben M, Beijnen JH, Schinkel AH.
    Mol Pharm; 2021 Dec 06; 18(12):4371-4384. PubMed ID: 34730366
    [Abstract] [Full Text] [Related]

  • 25. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
    van Hoppe S, Jamalpoor A, Rood JJM, Wagenaar E, Sparidans RW, Beijnen JH, Schinkel AH.
    Pharmacol Res; 2019 Aug 06; 146():104297. PubMed ID: 31175939
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
    Durmus S, Sparidans RW, van Esch A, Wagenaar E, Beijnen JH, Schinkel AH.
    Pharm Res; 2015 Jan 06; 32(1):37-46. PubMed ID: 24962512
    [Abstract] [Full Text] [Related]

  • 28. ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure.
    Rijmers J, Retmana IA, Bui V, Arguedas D, Lebre MC, Sparidans RW, Beijnen JH, Schinkel AH.
    Biomed Pharmacother; 2024 Jun 06; 175():116720. PubMed ID: 38733773
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.
    Wang J, Bruin MAC, Gan C, Lebre MC, Rosing H, Beijnen JH, Schinkel AH.
    Int J Pharm; 2020 May 15; 581():119277. PubMed ID: 32234426
    [Abstract] [Full Text] [Related]

  • 31. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML, Läppchen T, Jansen HT, Kivits S, van Driel A, van de Steeg E, van der Hoorn JW, Sio CF, Steinbach OC, DeGroot J.
    Nucl Med Biol; 2015 Nov 15; 42(11):833-41. PubMed ID: 26264927
    [Abstract] [Full Text] [Related]

  • 32. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
    Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH.
    J Pharmacol Exp Ther; 2012 Apr 15; 341(1):164-73. PubMed ID: 22238213
    [Abstract] [Full Text] [Related]

  • 33. P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.
    Tang SC, Kort A, Cheung KL, Rosing H, Fukami T, Durmus S, Wagenaar E, Hendrikx JJ, Nakajima M, van Vlijmen BJ, Beijnen JH, Schinkel AH.
    Mol Pharm; 2015 Oct 05; 12(10):3714-23. PubMed ID: 26317243
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).
    Wang Y, Sparidans RW, Potters S, Şentürk R, Lebre MC, Beijnen JH, Schinkel AH.
    Pharmaceuticals (Basel); 2021 Oct 27; 14(11):. PubMed ID: 34832869
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.